title: Multicenter phase II-III study of oxaliplatin plus cyclophosphamide vs. cisplatin plus cyclophosphamide in chemonaive advanced ovarian cancer patients.
abstract: OBJECTIVE
  A phase II-III randomised study to compare safety and efficacy of an oxaliplatin/cyclophosphamide (OXAC) combination, vs. the reference combination of cisplatin/cyclophosphamide (CPC), in untreated advanced ovarian cancer patients.
  
  
  METHODS
  182 patients were enrolled, of whom 177 were treated: 86 with OXAC (130 mg/m2 oxaliplatin two-hour intravenous (i.v.) infusion, 1,000 mg/m2 cyclophosphamide two-hour i.v. infusion), and 91 with CPC (100 mg/m2 cisplatin one-hour i.v. infusion. 1,000 mg/m2 cyclophosphamide two-hour i.v. infusion). Treatment cycles were repeated every three weeks (maximum of six cycles).
  
  
  RESULTS
  The main toxicities, which were significantly less severe in the OXAC arm, were myelosuppression and vomiting, including (OXAC vs CPC, % patients): grade 3-4 leukopenia (37% vs. 56%), and anaemia (7% vs. 32%), with blood transfusions in 8% vs. 21%. In the OXAC arm, 64% of surgically assessable patients and 33% of clinically assessable patients achieved an objective response. In the CPC arm, 67% patients achieved a surgical response and 42% achieved an objective clinical response. In the OXAC and CPC arms, median progression free-survival was 13.0 and 13.3 months, and overall survival was 36.0 and 25.1 months respectively, without statistically significant difference.
  
  
  CONCLUSIONS
  The activity and time-related parameters of the OXAC and CPC combinations in advanced ovarian cancer patients, are comparable. Combined with the better safety profile of the oxaliplatin-containing regimen, this confirms the interest of oxaliplatin combined with active new agents in this indication.
authors.affiliation: Fédération des Services des Maladies Sanguines Immunitaires et Tumorales, Hĵpital Paul Brousse, Villejuif, France. jean-louis.misset@sls.ap-hop-paris.fr
authors.forename: J L
authors.initials: JL
authors.lastname: Misset
authors.forename: P
authors.initials: P
authors.lastname: Vennin
authors.forename: P H
authors.initials: PH
authors.lastname: Chollet
authors.forename: P
authors.initials: P
authors.lastname: Pouillart
authors.forename: P H
authors.initials: PH
authors.lastname: Laplaige
authors.forename: J L
authors.initials: JL
authors.lastname: Frobert
authors.forename: D
authors.initials: D
authors.lastname: Castera
authors.forename: M
authors.initials: M
authors.lastname: Fabro
authors.forename: D
authors.initials: D
authors.lastname: Langlois
authors.forename: E
authors.initials: E
authors.lastname: Cortesi
authors.forename: V
authors.initials: V
authors.lastname: Lucas
authors.forename: E
authors.initials: E
authors.lastname: Gamelin
authors.forename: A
authors.initials: A
authors.lastname: Laadem
authors.forename: J
authors.initials: J
authors.lastname: Otero
mesh_terms: D000328:Adult; D000368:Aged; D000740:Anemia / Q000139:chemically induced; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000627:therapeutic use*; D002945:Cisplatin / Q000008:administration & dosage; D003520:Cyclophosphamide / Q000008:administration & dosage; D018572:Disease-Free Survival; D005260:Female; D006801:Humans; D007262:Infusions, Intravenous; D007970:Leukopenia / Q000139:chemically induced; D008875:Middle Aged; D009503:Neutropenia / Q000139:chemically induced; D009944:Organoplatinum Compounds / Q000008:administration & dosage; D010051:Ovarian Neoplasms / Q000188:drug therapy* / Q000473:pathology; D016896:Treatment Outcome; D014839:Vomiting / Q000139:chemically induced
chemical_list: D009944:Organoplatinum Compounds; D003520:Cyclophosphamide; D002945:Cisplatin